Message from the President

I am Toru Kimura, newly appointed as the Representative Director, President and CEO of Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Group has been operating every day to achieve its Mission "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By directing our efforts into the research and development, we aim to provide innovative and useful pharmaceutical and healthcare solutions to people in Japan and around the world to realize our Mission.

The new management team, including myself, is fully committed to overcoming current financial situation and striving for swift recovery and sustained growth.

We have positioned the fiscal year 2024 as a turning point for regrowth and have set a must-achieve goal to turn core operating profit positive. Although we already implemented significant rationalizations in the U.S. in the fiscal year 2023, we are actively streamlining our operations across the entire group, including Japan through efficient organizational management and thorough trimming costs to the minimum, while also promoting the efficient use of limited management resources. In North America, we will focus on maximizing the value of RETHYMIC as well as our three key products ORGOVYX, MYFEMBREE, and GEMTESA which contribute significantly to revenue. In our research and development activities, we will focus on pipeline selection and concentration, with a particular emphasis on the development of DSP-5336 and TP-3654 in the Oncology area, which are expected to contribute to early revenue growth, aiming for approval and market launch by the fiscal year 2027. In the Psychiatry & Neurology area, we will drive forward the program for the world's first practical application of allogenic iPS cell-derived dopaminergic neural progenitor cells, which we believe will be a game-changer in the treatment of Parkinson's disease.

While our goal of establishing a position as a "Global Specialized Player" by 2033 remains unchanged, we recognize the need to review our Mid-term Business Plan 2027 and expect to disclose a new Mid-term Business Plan promptly. Going forward, we will focus on our research and development activities in the Oncology and the Psychiatry & Neurology area as priority disease areas with high unmet medical needs, incorporating cutting-edge science to create innovative pharmaceuticals and Regenerative medicine/ Cell therapy products that lead the world. Moreover, we value proactive dialogue with diverse stakeholders, such as patients and their families, healthcare professionals, shareholders, investors, employees, business partners, and local communities. By strengthening our corporate governance framework and ensuring compliance in our business operations, we aim to enhance sustainable corporate value and contribute to the realization of a sustainable society.

All Sumitomo Pharma Group executives and employees will work together with a single purpose of doing our best to earn and maintain the trust of our stakeholders.

On behalf of all of us at Sumitomo Pharma, I would like to sincerely thank you for your ongoing support and encouragement.

Toru Kimura

Representative Director,
President and Chief Executive Officer
Sumitomo Pharma Co., Ltd.

(As of June 2024)